Background: Free thyroxine (FT 4 ) assays may exhibit biases that are related to serum T 4 binding capacity (sBC). We describe two tests that can be used to assess the presence and magnitude of sBC-dependent biases in FT 4 assays. Methods: We used a direct equilibrium dialysis FT 4 assay as the reference method and compared the results obtained with those of the FT 4 assays under investigation, in patient sera having a wide range of sBC. We then compared the expected and observed FT 4 results for sera diluted with an inert buffer. Because serum dilution causes a predictable decrease in sBC, an increasingly negative bias on progressive dilution is indicative of a sBC-dependent bias. Results: The automated FT 4 assay investigated (Vitros FT 4 ) showed no demonstrable sBC-dependent bias by either test. Conclusion: These two tests can be used to screen for sBC-dependent biases in FT 4 assays.
which is not bound by the thyroid hormone-binding proteins, and it is this free form of T 4 (FT 4 ) that is best correlated with thyroid status (1) (2) (3) . Because the proportion of total T 4 found in the free form is extremely small (ϳ0.02% in euthyroid subjects), its quantification in the presence of the relatively very high concentrations of T 4 bound to the binding proteins has proved exceedingly difficult. Indeed, an extensive literature exists highlighting interferences experienced with many commercially available FT 4 assays (4 -10 ) . More recently, FT 4 assays have become automated, which makes their use even more attractive to laboratories and has fueled the move from total to free thyroid hormone measurement. Although the newer FT 4 assays are substantially better than the original assays, few seem to be as analytically accurate as the direct equilibrium dialysis (ED) FT 4 
method (9 ).
Several studies have highlighted weaknesses in assay designs that produce significant biases (7, 9, 11, 12 ) , the magnitude of which are assay specific and related to the concentration of the protein-bound T 4 (PBT 4 ). In particular, Nelson et al. (9 ) have shown that as the concentration of PBT 4 decreased, the magnitude of the negative bias seen was increased. Careful examination of the experimental design adopted and data presented by Nelson et al. (9 ) suggested that the method-specific biases observed were dependent not only on the concentration of PBT 4 , but also on the serum binding capacity (sBC; calculated as the concentration ϫ the affinity of free binding proteins).
In the present study, we examine the ability of two simple experimental tests in identifying the presence and magnitude of sBC-dependent biases in an automated FT 4 assay (Vitros FT 4 ). Both of these tests challenge the FT 4 assays in the clinical situations outlined recently by the National Academy of Clinical Biochemistry (13 ), i.e., determination of the assay-specific biases in sera having a broad spectrum of binding protein abnormalities. For the first test, we used sera from patients having a wide sBC range. To ensure that the widest possible range of sBC was challenged, the test panel included sera from pregnant women in their third trimester, ambulatory subjects, and severely ill hospitalized patients because these groups previously have been shown to have high, normal, and low sBC, respectively. For the second test, variation of sBC was achieved by the serial dilution of third trimester sera in an inert buffer.
Materials and Methods
The patient panel examined in the assays described below consisted of 26 ambulatory subjects, 18 women at the third trimester of pregnancy, and 25 severely ill patients who were admitted to an intensive care unit with a variety of illnesses, including sepsis, cardiac arrest, cardiac failure, and respiratory failure. All procedures used were in accordance with the Helsinki Declaration of 1975 (as revised in 1996). The patient sera were collected for routine analyses and were kept frozen (Ϫ20°C) until required for the hormone measurements performed as part of the present study. All assays (with the exception of the ED FT 4 , which was performed in the Cardiff laboratories of Ortho-Clinical Diagnostics) were carried out at the Clinical Biochemistry Laboratory of the Royal Infirmary, Edinburgh.
The sBC and PBT 4 concentrations of three sera were reduced in vitro by serially diluting (2-to 64-fold dilutions) sera in 10 mmol/L HEPES (Sigma Chemical; cat. no. H3375) buffer solution, pH 7.4. The sera chosen were from third-trimester pregnancies because these represented sera with high sBC and PBT 4 concentrations. The undiluted and diluted samples were assayed in the two FT 4 methods using standard protocols.
The automated FT 4 method used was the Vitros Immunodiagnostic Products (Ortho-Clinical Diagnostics, Amersham UK). The manual direct ED method was the Nichols FT 4 method (Nichols Institute Diagnostics). The physicochemical principles of the assays used are fundamentally different. The Vitros FT 4 assay is a labeled antibody method (2, 14 ) , and the Nichols assay is a direct equilibrium method (15 ) .
The ED method is carried out by dialyzing the FT 4 from 200 L of serum into 2.4 mL of dialysis buffer (at 37°C, over a 16-to 18-h incubation period). The FT 4 in the protein-free dialysate is then quantified by a sensitive solid-phase RIA for T 4 . To minimize variability (e.g., assay-to-assay variation), all samples studied were analyzed on one occasion, with the samples randomized. The package insert quotes an intraassay CV at doses falling within and above the euthyroid range as being Ͻ13%. The euthyroid FT 4 range, which was the observed range with one outlier deleted from each end, quoted in the package insert is 10.3-34.7 pmol/L.
In the Vitros FT 4 assay, 25 L of sample is pipetted into microwells coated with a triiodothyronine (T 3 )-protein conjugate, followed by 100 L of a sheep anti-T 4 antibody labeled with horse-radish peroxidase in a 150 mmol/L phosphate buffer containing 1.0 g/L bovine gelatin and 1.0 g/L bovine ␥-globulin. During the 16-min incubation at 37°C, a proportion of the labeled antibody binds to the serum FT 4 and to the well surface, with the amount binding to the well surface being inversely related to the serum FT 4 concentration. The well is then washed, and a signal reagent that produces luminescence is then added; the resulting light emitted is measured in a luminometer. All procedures are carried out automatically by the Vitros ECi Immunodiagnostic system. The samples were assayed in a batch mode, with quality-control samples at three concentrations run at the beginning and end of the assay. The within-run imprecision for FT 4 values in the euthyroid and hyperthyroid range is quoted in the package insert as being Ͻ3%. The assay was calibrated using an in-house ED assay. The euthyroid range (1 and 99 percentiles) quoted in the package insert is 10 -28.2 pmol/L.
In addition to the FT 4 assays, the patient sera were also analyzed in the Vitros Immunodiagnostic Products Total T 4 (TT4) and T 3 uptake (T3U) assays. The euthyroid T 4 range (2.5 and 97.5 percentiles) quoted in the package insert is 71.2-141 nmol/L. The T3U assay is calibrated in %T3U units, which are inversely related to the serum binding capacity (i.e., a serum with a high %T3U has a low binding capacity). The euthyroid %T3U range (2.5 and 97.5 percentiles) quoted in the package insert is 23.5-40.6% uptake.
All assays were performed following the manufacturers' instructions.
statistics
Analysis of data was carried out by standard methods with Microsoft Excel spreadsheets. The dependence of the FT 4 bias observed with any variable was determined by correlating (linear regression analysis performed by the least-squares method) the methodological difference (from ED FT 4 ) of each patient (y-axis) against the variable studied (x-axis). The sBC was calculated by dividing the Vitros TT4 concentration by the ED FT 4 concentration (9 ). The concentration of PBT 4 was estimated by subtracting the concentration of FT 4 , as measured by ED, from the concentration of TT4 (9 ) . Because the FT 4 concentration relative to TT4 was small (Ͻ0.1% of the TT4), the PBT 4 concentration showed little difference from the TT4 concentration. The agreement between the Vitros FT 4 and the manual ED FT 4 was tested by Deming regression (16 ) . A measure of the sBC was also obtained by the T3U, where the %T3U is inversely related to the binding capacity. The Student unpaired t-test was used to compare the biochemical profiles between the patient groups (within each assay format), and the paired t-test was used when the comparison was across different assay methods.
Results
The quality-control sera used in each assay were all within expected ranges, and there was no evidence of drift in performance in any of the assays examined.
The relationship between the Vitros FT 4 and ED FT 4 assays in all patients studied is shown in Fig. 1 Table 1 shows the mean (Ϯ SD) and observed ranges for the two FT 4 methods under investigation (FT 4 in pmol/L), the TT4 (in nmol/L), %T3U, and sBC (in nmol/ pmol) in the ambulatory, pregnant, and hospitalized patients. The FT 4 concentration, as measured by both FT 4 methods, in the hospitalized group was significantly (P Ͻ0.001) higher than the FT 4 concentration in the ambulatory group. None of the patients in the hospitalized group had FT 4 concentrations below the corresponding euthyroid range of the two FT 4 assays examined. The calculated sBC in the hospitalized group was significantly lower (P Ͻ0.001) than that found in the ambulatory group, whereas the corresponding %T3U value was significantly higher (P Ͻ0.001). Thus, both measures of serum T 4 binding support the view that hospitalized patients have decreased serum T 4 binding capacities. The TT4 concentration in the hospitalized group was significantly lower (P Ͻ0.001) than that obtained in the ambulatory group, and 12 of the 25 hospitalized patients had TT4 concentrations below the euthyroid range. The FT 4 concentration in the pregnancy group was significantly lower (P Ͻ0.001) than in the ambulatory group with both FT 4 methods, whereas the sBC and TT4 concentrations were increased (P Ͻ0.001). As expected, the %T3U was significantly (P Ͻ0.001) reduced.
The FT 4 concentrations obtained in the pregnancy group by the Vitros method were higher than the corresponding concentration obtained with the ED method. These differences, although small (mean difference, 2.6 pmol/L; range of difference in 95% confidence intervals, 2.1-3.2 pmol/L), were statistically significant (P Ͻ0.001). Similar differences from ED FT 4 were seen in the ambulatory group (mean difference, 1.6 pmol/L; range of differences in 95% confidence intervals, 0.7 to 2.6 pmol/L; both P Ͻ0.001). The Vitros FT 4 concentration in the hospitalized group was not significantly different (P Ͼ0.05) from the mean concentration obtained in the ED method. yielded a significant slope and r value, both at P Ͻ0.05, was the pregnancy group) indicates that at the highest observed sBC (23.9 nmol/pmol), the Vitros FT 4 will be positively biased by 4 pmol/L (95% confidence interval, 2.6 -5.4 pmol/L). There was no apparent relationship (P Ͼ0.05) between the PBT 4 concentrations and the Vitros FT 4 concentrations in any of the patient groups studies. The results of the serum dilution experiment performed on the pregnancy sera are shown in Fig. 4 . The theoretically derived FT 4 concentrations suggest that the decrease after a 32-fold dilution will be Ͻ1%. Similarly, the FT 4 concentration as measured by ED was only slightly affected by serum dilution. At dilutions of 1:16 and 1:32 (i.e., dilutions that are expected to decrease the sBC to levels usually seen in some hospitalized patients) the ED FT 4 was within 5% of the concentration obtained in the undiluted sample. The Vitros FT 4 concentrations at these dilutions did not vary significantly (Ͻ5%) from the FT 4 concentration obtained in the undiluted sample.
Discussion
It is now accepted that FT 4 shows a better correlation to the thyroid status than total T 4 (1-3 ) ; thus it is the free hormone fraction that should be used to confirm the diagnosis of thyroid disease (17) (18) (19) . The direct measurement of FT 4 has, however, proved to be exceedingly difficult. Over the last two decades, numerous methodologies have been developed, and their limitations have been the subject of many publications and heated discussions in the literature (3, 7, 11, 20 -28 ) . Several limitations (e.g., "albumin" effects) of the early FT 4 assays have been eliminated or minimized, but as shown recently, large methodological differences are still present (9 ) . In their study, Nelson et al (9 ) measured FT 4 (using different FT 4 RIAs) in serum preparations in which the concentration of PBT 4 (and sBC) was altered, whereas the ED FT 4 concentration was kept constant. The results showed that the three FT 4 methods studied were significantly, but to varying degrees, influenced by the serum PBT 4 . This method-specific dependency on PBT 4 was proposed as a possible explanation for the discordant FT 4 measurements seen in nonthyroidal illness. In an additional study, this Fig. 2 . Relationship between the Vitros FT 4 bias (determined by ED FT 4 ) and sBC in ambulatory (ࡗ), hospitalized (f), and pregnant (‚) subjects. Fig. 3 . Relationship between the Vitros FT 4 bias (determined by ED FT 4 ) and %T3U in ambulatory (ࡗ), hospitalized (f), and pregnant (‚) subjects. (10 ) suggested that the methodspecific PBT 4 dependency was a direct result of increased sequestration of T 4 by the assay reagents.
Clinical Chemistry
We have used two simple tests to examine the bias of an automated (Vitros) FT 4 method. The first test involved the comparison of the FT 4 results obtained in the Vitros method in patients having a wide range of binding capacities against those obtained in a commercial direct ED system. The main reason for choosing ED as the reference method is that it is one of the methods, in addition to ultrafiltration, generally considered as the "gold standard" method for free thyroid hormone measurement. However, even these gold standards have their own inconsistencies and technical weaknesses (15, 29 -32 ) . Thus, the elevation of this particular ED method as the definitive gold standard method is arguable. Nonetheless, the validity of the ED method chosen has been well documented (15 ) , although even this ED may be biased in some nonthyroidal illness sera because of dilution effects during the dialysis step (33 ) . The ED method we used produces a 13-fold dilution of dialyzable substances in sera. The patient categories included in the study have been documented to have high (i.e., thirdtrimester pregnancy) and low (i.e., hospitalized patients) binding capacities (13 ) . This binding capacity profile has been confirmed in the present study by two independent methods (the sBC, derived by dividing the TT4 result by the ED FT 4 result, and the %T3U). The second test used examined the effect of serum dilution on the FT 4 concentration obtained by the methods under investigation (Vitros and ED FT 4 ). The sample dilution test was chosen for several reasons: (a) one can alter the sBC in a predictable fashion (e.g., a twofold dilution will reduce the sBC by ϳ50%); (b) one can readily predict the ideal performance of an assay and thus eliminate the need to compare results with those obtained by a reference method; (c) one can "manufacture" serum dilution pools whose sBCs mimic the range of sBCs found in patients [e.g., the sBC concentration range in patients undergoing thyroid testing has been shown to be ϳ30-fold (13 ) ; thus dilution of a pregnant serum by this factor will encompass the sBC likely to be experienced by a laboratory]; and (d) this test can easily be performed by any user.
The law of mass action (2, 3 ) dictates that the concentration of FT 4 in serum depends on the equilibrium that exists between the PBT 4 and the concentration and affinity (i.e., the sBC) of the free binding sites:
In estimating the sBC (i.e., PBT 4 /FT 4 ) we made the same assumption as Nelson and co-workers (9, 13 ) , which is that the FT 4 as measured by ED gives an unbiased estimate of the true FT 4 . As discussed previously, this assumption is arguable. The highest and lowest individual sBC values in our study population were 23.9 and 1.2 nmol/pmol, which represent a range of 19.9-fold. Thus, it is clear from this and other studies (9, 13 ) that patients undergoing thyroid function tests possess a very wide range of serum T 4 binding (and consequently wide ranges of PBT 4 ). The results presented here show that the FT 4 concentrations obtained by the Vitros assay (relative to ED), were not dependent on T 4 binding (sBC or T3U) or PBT 4 . The small positive bias (from ED) seen in pregnancy is likely because of calibration differences. This is supported by the fact that the corresponding FT 4 concentrations in the ambulatory group were also positively biased to a similar degree.
In the second test, we examined the FT 4 biases of the two methods (Vitros and ED FT 4 ) by analyzing sera whose protein concentrations were decreased in vitro. Lowering of the sBC by decreasing the concentration of the binding proteins was accomplished by diluting sera in an inert buffer (HEPES). The FT 4 concentrations as measured by both the ED and Vitros methods were not reduced by the serum dilution.
The estimation of serum FT 4 by immunoassay, irrespective of the methodology used will invariably disturb the normal equilibrium between PBT 4 and sBC (2, 3 ) . This will come about as a result of the addition of the antibody and the dilution of the sample in assay reagents that may also contain T 4 binders such as albumin or animal sera, which are often added to protect assays from interferences from heterophilic antibodies. These additions will lead to the establishment of a new equilibrium and a new "in vitro" FT 4 concentration. The concentration of this in vitro FT 4 will be dictated by the in vitro bound T 4 and unbound binding site concentrations. The in vitro bound T 4 will be the net sum of PBT 4 and T 4 bound by the immunoassay reagents (iPBT 4 ), and the in vitro unbound binding sites will include, in addition to sBC, the free antibody-binding sites and the free binding sites of other binders included in the reagents [i.e., immunoassay binding capacity (iBC), which will be equal to the affinity ϫ concentration of the free immunoassay binding sites]. Thus, the in vitro FT 4 will be equal to (PBT 4 ϩ iPBT 4 )/ (sBC ϩ iBC). From this formula, one can predict that a high iBC will cause biases that will be dependent on the magnitude of the endogenous sBC. Thus, as the sBC decreases (as seen in hospitalized patients and mimicked by serum dilution), the assay will yield increasingly negative results. The results presented show a lack of sBC-dependent biases in both the Vitros and the ED FT 4 assays, suggesting that the in vitro disturbance of the T 4 /protein equilibrium induced by both assays is negligible.
The tests described in the present study can be used to assess the presence and magnitude of sBC-dependent biases of other commercial FT 4 methods.
